Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
EMBOLD SCLC-301
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- NCT07099898 ↗
- Recruiting
- GlaxoSmithKline
- Focused
We haven't built an HCP commentary report on EMBOLD SCLC-301 (risvutatug rezetecan and topotecan in Neoplasms, Lung) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on EMBOLD SCLC-301 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 4 |
The trial
ClinicalTrials.gov- Official title
- Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Neoplasms, Lung
- Interventions
- Risvutatug rezetecan (Ris-Rez); Topotecan
- Arms
- Risvutatug rezetecan (Ris-Rez) · Experimental
- Topotecan · Active comparator
- Enrollment
- 420 (estimated)
- Primary outcomes
- Overall Survival (OS)
- Sponsor
- GlaxoSmithKline
- Start
- Aug 11, 2025
- Primary completion
- Nov 5, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT07099898 · updated Oct 20, 2026